Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Myelodysplastic Syndrome Harboring Trisomy 8

Adult Myelodysplastic Syndrome Working Group of the Japan Society for Hematopoietic Cell Transplantation

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Trisomy 8 (+8) is 1 of the most common cytogenetic abnormalities in adult patients with myelodysplastic syndrome (MDS). However, the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) in adult patients with MDS harboring +8 remains unclear. To evaluate the outcome and prognostic factors in patients with MDS harboring +8 as the sole cytogenetic abnormality or in association with other abnormalities, we retrospectively analyzed the Japanese registration data of 381 adult patients with MDS harboring +8 treated with allogeneic HSCT between 1990 and 2013. With a median follow-up period of 53 months, the probability of overall survival and cumulative incidence of relapse at 4 years were 51% and 22%, respectively. In the multivariate analysis, age > 50 years, 2 or more additional cytogenetic abnormalities, and a high risk at the time of HSCT according to the FAB/WHO classification were significantly associated with a higher overall mortality. Nevertheless, no significant impact of the outcome was observed in patients with 1 cytogenetic abnormality in addition to +8. Although 221 patients (58%) had advanced MDS at the time of HSCT, allogeneic HSCT offered a curative option for adult patients with MDS harboring +8.

Original languageEnglish
Pages (from-to)75-80
Number of pages6
JournalBiology of Blood and Marrow Transplantation
Volume23
Issue number1
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Hematopoietic Stem Cell Transplantation
Myelodysplastic Syndromes
Chromosome Aberrations
Trisomy Chromosome 8
Multivariate Analysis
Recurrence
Survival
Mortality
Incidence

Keywords

  • Additional abnormality
  • Allogeneic hematopoietic stem cell transplantation
  • Cytogenetics
  • Myelodysplastic syndrome
  • Trisomy 8

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Myelodysplastic Syndrome Harboring Trisomy 8. / Adult Myelodysplastic Syndrome Working Group of the Japan Society for Hematopoietic Cell Transplantation.

In: Biology of Blood and Marrow Transplantation, Vol. 23, No. 1, 01.01.2017, p. 75-80.

Research output: Contribution to journalArticle

Adult Myelodysplastic Syndrome Working Group of the Japan Society for Hematopoietic Cell Transplantation 2017, 'Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Myelodysplastic Syndrome Harboring Trisomy 8', Biology of Blood and Marrow Transplantation, vol. 23, no. 1, pp. 75-80. https://doi.org/10.1016/j.bbmt.2016.10.015
Adult Myelodysplastic Syndrome Working Group of the Japan Society for Hematopoietic Cell Transplantation. / Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Myelodysplastic Syndrome Harboring Trisomy 8. In: Biology of Blood and Marrow Transplantation. 2017 ; Vol. 23, No. 1. pp. 75-80.
@article{2c360fabba48462383bf98257128ed2c,
title = "Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Myelodysplastic Syndrome Harboring Trisomy 8",
abstract = "Trisomy 8 (+8) is 1 of the most common cytogenetic abnormalities in adult patients with myelodysplastic syndrome (MDS). However, the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) in adult patients with MDS harboring +8 remains unclear. To evaluate the outcome and prognostic factors in patients with MDS harboring +8 as the sole cytogenetic abnormality or in association with other abnormalities, we retrospectively analyzed the Japanese registration data of 381 adult patients with MDS harboring +8 treated with allogeneic HSCT between 1990 and 2013. With a median follow-up period of 53 months, the probability of overall survival and cumulative incidence of relapse at 4 years were 51{\%} and 22{\%}, respectively. In the multivariate analysis, age > 50 years, 2 or more additional cytogenetic abnormalities, and a high risk at the time of HSCT according to the FAB/WHO classification were significantly associated with a higher overall mortality. Nevertheless, no significant impact of the outcome was observed in patients with 1 cytogenetic abnormality in addition to +8. Although 221 patients (58{\%}) had advanced MDS at the time of HSCT, allogeneic HSCT offered a curative option for adult patients with MDS harboring +8.",
keywords = "Additional abnormality, Allogeneic hematopoietic stem cell transplantation, Cytogenetics, Myelodysplastic syndrome, Trisomy 8",
author = "{Adult Myelodysplastic Syndrome Working Group of the Japan Society for Hematopoietic Cell Transplantation} and Takaaki Konuma and Yasushi Miyazaki and Naoyuki Uchida and Kazuteru Ohashi and Tadakazu Kondo and Hirohisa Nakamae and Satoshi Takahashi and Takehiko Mori and Yukiyasu Ozawa and Chiaki Kato and Koji Iwato and Takahiro Fukuda and Tatsuo Ichinohe and Yoshiko Atsuta and Ken Ishiyama",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.bbmt.2016.10.015",
language = "English",
volume = "23",
pages = "75--80",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Myelodysplastic Syndrome Harboring Trisomy 8

AU - Adult Myelodysplastic Syndrome Working Group of the Japan Society for Hematopoietic Cell Transplantation

AU - Konuma, Takaaki

AU - Miyazaki, Yasushi

AU - Uchida, Naoyuki

AU - Ohashi, Kazuteru

AU - Kondo, Tadakazu

AU - Nakamae, Hirohisa

AU - Takahashi, Satoshi

AU - Mori, Takehiko

AU - Ozawa, Yukiyasu

AU - Kato, Chiaki

AU - Iwato, Koji

AU - Fukuda, Takahiro

AU - Ichinohe, Tatsuo

AU - Atsuta, Yoshiko

AU - Ishiyama, Ken

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Trisomy 8 (+8) is 1 of the most common cytogenetic abnormalities in adult patients with myelodysplastic syndrome (MDS). However, the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) in adult patients with MDS harboring +8 remains unclear. To evaluate the outcome and prognostic factors in patients with MDS harboring +8 as the sole cytogenetic abnormality or in association with other abnormalities, we retrospectively analyzed the Japanese registration data of 381 adult patients with MDS harboring +8 treated with allogeneic HSCT between 1990 and 2013. With a median follow-up period of 53 months, the probability of overall survival and cumulative incidence of relapse at 4 years were 51% and 22%, respectively. In the multivariate analysis, age > 50 years, 2 or more additional cytogenetic abnormalities, and a high risk at the time of HSCT according to the FAB/WHO classification were significantly associated with a higher overall mortality. Nevertheless, no significant impact of the outcome was observed in patients with 1 cytogenetic abnormality in addition to +8. Although 221 patients (58%) had advanced MDS at the time of HSCT, allogeneic HSCT offered a curative option for adult patients with MDS harboring +8.

AB - Trisomy 8 (+8) is 1 of the most common cytogenetic abnormalities in adult patients with myelodysplastic syndrome (MDS). However, the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) in adult patients with MDS harboring +8 remains unclear. To evaluate the outcome and prognostic factors in patients with MDS harboring +8 as the sole cytogenetic abnormality or in association with other abnormalities, we retrospectively analyzed the Japanese registration data of 381 adult patients with MDS harboring +8 treated with allogeneic HSCT between 1990 and 2013. With a median follow-up period of 53 months, the probability of overall survival and cumulative incidence of relapse at 4 years were 51% and 22%, respectively. In the multivariate analysis, age > 50 years, 2 or more additional cytogenetic abnormalities, and a high risk at the time of HSCT according to the FAB/WHO classification were significantly associated with a higher overall mortality. Nevertheless, no significant impact of the outcome was observed in patients with 1 cytogenetic abnormality in addition to +8. Although 221 patients (58%) had advanced MDS at the time of HSCT, allogeneic HSCT offered a curative option for adult patients with MDS harboring +8.

KW - Additional abnormality

KW - Allogeneic hematopoietic stem cell transplantation

KW - Cytogenetics

KW - Myelodysplastic syndrome

KW - Trisomy 8

UR - http://www.scopus.com/inward/record.url?scp=85006459142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006459142&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2016.10.015

DO - 10.1016/j.bbmt.2016.10.015

M3 - Article

C2 - 27777139

AN - SCOPUS:85006459142

VL - 23

SP - 75

EP - 80

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 1

ER -